FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035481305> ?p ?o ?g. }

• W2035481305 endingPage "309.e11" @default.
• W2035481305 startingPage "302" @default.
• W2035481305 abstract "Background & AimsCombination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn’s disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-related cancer and infection. After accounting for these risks, the strategy yielding the greatest benefit may vary with age.MethodsWe assessed age-specific risks and benefits of combination therapy compared with infliximab monotherapy by using Markov modeling. The base case was a 35-year-old male patient with a 1-year time horizon. We assumed the incidence of lymphoma to be 5.28-fold higher with combination therapy. Secondary analyses accounted for life expectancy, therapy beyond 1 year, and age-specific surgical and infection risks. Quality-adjusted life years (QALYs) were calculated for 25- to 75-year old individuals.ResultsCombination therapy was found to be of greater benefit in the base case (0.7522 QALYs for combination therapy vs 0.7426 QALYs for monotherapy). Accounting for life years lost, monotherapy was the best approach if the hazard ratio for lymphoma with combination therapy was >8.1 patients who were 75 years old. Monotherapy provided greater net benefit to patients 55, 65, or 75 years old if therapy was extended for 9, 7, or 5 years, respectively. For 25-year-old men, monotherapy resulted in fewer deaths but only yielded greater QALYs if the annual incidence of hepatosplenic T-cell lymphoma exceeded 36/100,000 persons.ConclusionsAfter accounting for age-specific risks of lymphoma, infection, and surgical complications, benefits of combination therapy outweighed the risks as a short-term and intermediate-term strategy for most patients with moderate-to-severe Crohn’s disease who were younger than 65 years. For young male patients, combination therapy yields greater QALYs but at cost of an increased risk of death from lymphoma. Combination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn’s disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-related cancer and infection. After accounting for these risks, the strategy yielding the greatest benefit may vary with age. We assessed age-specific risks and benefits of combination therapy compared with infliximab monotherapy by using Markov modeling. The base case was a 35-year-old male patient with a 1-year time horizon. We assumed the incidence of lymphoma to be 5.28-fold higher with combination therapy. Secondary analyses accounted for life expectancy, therapy beyond 1 year, and age-specific surgical and infection risks. Quality-adjusted life years (QALYs) were calculated for 25- to 75-year old individuals. Combination therapy was found to be of greater benefit in the base case (0.7522 QALYs for combination therapy vs 0.7426 QALYs for monotherapy). Accounting for life years lost, monotherapy was the best approach if the hazard ratio for lymphoma with combination therapy was >8.1 patients who were 75 years old. Monotherapy provided greater net benefit to patients 55, 65, or 75 years old if therapy was extended for 9, 7, or 5 years, respectively. For 25-year-old men, monotherapy resulted in fewer deaths but only yielded greater QALYs if the annual incidence of hepatosplenic T-cell lymphoma exceeded 36/100,000 persons. After accounting for age-specific risks of lymphoma, infection, and surgical complications, benefits of combination therapy outweighed the risks as a short-term and intermediate-term strategy for most patients with moderate-to-severe Crohn’s disease who were younger than 65 years. For young male patients, combination therapy yields greater QALYs but at cost of an increased risk of death from lymphoma." @default.
• W2035481305 created "2016-06-24" @default.
• W2035481305 creator A5004110157 @default.
• W2035481305 creator A5016997889 @default.
• W2035481305 creator A5055266545 @default.
• W2035481305 creator A5056339603 @default.
• W2035481305 creator A5066241193 @default.
• W2035481305 creator A5067719692 @default.
• W2035481305 date "2015-02-01" @default.
• W2035481305 modified "2023-10-07" @default.
• W2035481305 title "The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model" @default.
• W2035481305 cites W1645395964 @default.
• W2035481305 cites W1853249566 @default.
• W2035481305 cites W1902111455 @default.
• W2035481305 cites W1970754981 @default.
• W2035481305 cites W1983177884 @default.
• W2035481305 cites W1991334020 @default.
• W2035481305 cites W1991810959 @default.
• W2035481305 cites W2002647452 @default.
• W2035481305 cites W2002780176 @default.
• W2035481305 cites W2008365376 @default.
• W2035481305 cites W2010767372 @default.
• W2035481305 cites W2014075805 @default.
• W2035481305 cites W2015408970 @default.
• W2035481305 cites W2018771885 @default.
• W2035481305 cites W2019886362 @default.
• W2035481305 cites W2028995820 @default.
• W2035481305 cites W2030086403 @default.
• W2035481305 cites W2036139910 @default.
• W2035481305 cites W2070246874 @default.
• W2035481305 cites W2080450248 @default.
• W2035481305 cites W2088513474 @default.
• W2035481305 cites W2093504865 @default.
• W2035481305 cites W2100942700 @default.
• W2035481305 cites W2118559127 @default.
• W2035481305 cites W2121609590 @default.
• W2035481305 cites W2126807394 @default.
• W2035481305 cites W2151853252 @default.
• W2035481305 cites W2152096308 @default.
• W2035481305 cites W2152381563 @default.
• W2035481305 cites W2160917743 @default.
• W2035481305 cites W2165765440 @default.
• W2035481305 cites W4231630787 @default.
• W2035481305 cites W4236521244 @default.
• W2035481305 cites W2080550556 @default.
• W2035481305 doi "https://doi.org/10.1016/j.cgh.2014.07.058" @default.
• W2035481305 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4324381" @default.
• W2035481305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25117775" @default.
• W2035481305 hasPublicationYear "2015" @default.
• W2035481305 type Work @default.
• W2035481305 sameAs 2035481305 @default.
• W2035481305 citedByCount "33" @default.
• W2035481305 countsByYear W20354813052015 @default.
• W2035481305 countsByYear W20354813052016 @default.
• W2035481305 countsByYear W20354813052017 @default.
• W2035481305 countsByYear W20354813052018 @default.
• W2035481305 countsByYear W20354813052019 @default.
• W2035481305 countsByYear W20354813052020 @default.
• W2035481305 countsByYear W20354813052021 @default.
• W2035481305 countsByYear W20354813052022 @default.
• W2035481305 countsByYear W20354813052023 @default.
• W2035481305 crossrefType "journal-article" @default.
• W2035481305 hasAuthorship W2035481305A5004110157 @default.
• W2035481305 hasAuthorship W2035481305A5016997889 @default.
• W2035481305 hasAuthorship W2035481305A5055266545 @default.
• W2035481305 hasAuthorship W2035481305A5056339603 @default.
• W2035481305 hasAuthorship W2035481305A5066241193 @default.
• W2035481305 hasAuthorship W2035481305A5067719692 @default.
• W2035481305 hasBestOaLocation W20354813052 @default.
• W2035481305 hasConcept C120665830 @default.
• W2035481305 hasConcept C121332964 @default.
• W2035481305 hasConcept C126322002 @default.
• W2035481305 hasConcept C133925201 @default.
• W2035481305 hasConcept C141071460 @default.
• W2035481305 hasConcept C207103383 @default.
• W2035481305 hasConcept C2776760755 @default.
• W2035481305 hasConcept C2776999253 @default.
• W2035481305 hasConcept C2777138892 @default.
• W2035481305 hasConcept C2779134260 @default.
• W2035481305 hasConcept C2908647359 @default.
• W2035481305 hasConcept C44249647 @default.
• W2035481305 hasConcept C61511704 @default.
• W2035481305 hasConcept C71924100 @default.
• W2035481305 hasConcept C99454951 @default.
• W2035481305 hasConceptScore W2035481305C120665830 @default.
• W2035481305 hasConceptScore W2035481305C121332964 @default.
• W2035481305 hasConceptScore W2035481305C126322002 @default.
• W2035481305 hasConceptScore W2035481305C133925201 @default.
• W2035481305 hasConceptScore W2035481305C141071460 @default.
• W2035481305 hasConceptScore W2035481305C207103383 @default.
• W2035481305 hasConceptScore W2035481305C2776760755 @default.
• W2035481305 hasConceptScore W2035481305C2776999253 @default.
• W2035481305 hasConceptScore W2035481305C2777138892 @default.
• W2035481305 hasConceptScore W2035481305C2779134260 @default.
• W2035481305 hasConceptScore W2035481305C2908647359 @default.
• W2035481305 hasConceptScore W2035481305C44249647 @default.
• W2035481305 hasConceptScore W2035481305C61511704 @default.
• W2035481305 hasConceptScore W2035481305C71924100 @default.

• next